EAM
DRUG

Exome Asset Management’s Bright Minds Biosciences DRUG Stock Holding History

Exome Asset Management’s Portfolio DRUG Stock Details DRUG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$710K Buy
+10,110
New +$794K 0.44% 49

Other funds holding DRUG

JT
Jupiter Topco New York $245B AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Exome Asset Management's DRUG Position: Q2 2026 in Review

Exome Asset Management opened a new position in Bright Minds Biosciences (DRUG) in Q2 2026: 10,110 shares worth $710K. The stake represents 0.44% of the portfolio and ranks #49 among its holdings.

100 funds tracked by Wall St. Rank hold DRUG as of Q2 2026.

  • Exome Asset Management held 10,110 shares of Bright Minds Biosciences worth $710K as of Q2 2026.
  • Bright Minds Biosciences was a new Exome Asset Management position in Q2 2026.
  • Bright Minds Biosciences made up 0.44% of Exome Asset Management's portfolio in Q2 2026, its #49 holding.
  • 100 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q2 2026.

Based on Exome Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.